The application of CRISPR-Cas9 gene editing to hereditary cardiomyopathies has moved from theoretical promise to clinical reality in 2026. Three Phase II trials — conducted independently in the United States, the United Kingdom, and Japan — have reported statistically significant improvements in left ventricular ejection fraction and a reduction in sudden cardiac death risk among participants with hypertrophic cardiomyopathy caused by MYH7 gene mutations.
The most compelling data comes from the CardioGene-HCM trial, which enrolled 180 patients across 12 centres. At the 12-month follow-up, 71% of participants in the CRISPR intervention arm showed normalisation of septal wall thickness, compared to 8% in the standard-of-care control group. Adverse events were limited to transient inflammatory responses in 12% of treated patients, all of which resolved without long-term sequelae.
The mechanistic breakthrough enabling these results is a novel lipid nanoparticle delivery system developed at the Broad Institute, which achieves cardiomyocyte-specific delivery with 94% efficiency — a critical improvement over previous vectors that had off-target effects in hepatic tissue.
Regulatory implications are moving quickly. The FDA's Cardiovascular and Renal Drugs Advisory Committee is expected to convene a special session in Q3 2026 to evaluate an accelerated approval pathway for CRISPR-based HCM therapies. The European Medicines Agency has already granted PRIME designation to two candidate therapies.
About the Author
A leading expert contributing to global medical knowledge through Healthcore Bridge. Their research and clinical insights help shape the agenda at international medical conferences worldwide.